News
GSK shares fall after FDA panel votes against Blenrep combinations for myeloma
Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab mafodotin-blmf) combinations for treating relapsed or refractory multiple myeloma.
The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...
GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback